Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries
- PMID: 23645382
- DOI: 10.1007/s10928-013-9318-0
Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries
Abstract
Beta regression models have been recommended for continuous bounded outcome scores that are often collected in clinical studies. Implementing beta regression in NONMEM presents difficulties since it does not provide gamma functions required by the beta distribution density function. The objective of the study was to implement mixed-effects beta regression models in NONMEM using Nemes' approximation to the gamma function and to evaluate the performance of the NONMEM implementation of mixed-effects beta regression in comparison to the commonly used SAS approach. Monte Carlo simulations were conducted to simulate continuous outcomes within an interval of (0, 70) based on a beta regression model in the context of Alzheimer's disease. Six samples per subject over a 3 years period were simulated at 0, 0.5, 1, 1.5, 2, and 3 years. One thousand trials were simulated and each trial had 250 subjects. The simulation-reestimation exercise indicated that the NONMEM implementation using Laplace and Nemes' approximations provided only slightly higher bias and relative RMSE (RRMSE) compared to the commonly used SAS approach with adaptive Gaussian quadrature and built-in gamma functions, i.e., the difference in bias and RRMSE for fixed-effect parameters, random effects on intercept, and the precision parameter were <1-3 %, while the difference in the random effects on the slope was <3-7 % under the studied simulation conditions. The mixed-effect beta regression model described the disease progression for the cognitive component of the Alzheimer's disease assessment scale from the Alzheimer's Disease Neuroimaging Initiative study. In conclusion, with Nemes' approximation of the gamma function, NONMEM provided comparable estimates to those from SAS for both fixed and random-effect parameters. In addition, the NONMEM run time for the mixed beta regression models appeared to be much shorter compared to SAS, i.e., 1-2 versus 20-40 s for the model and data used in the manuscript.
Similar articles
-
Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.AAPS J. 2014 Nov;16(6):1271-81. doi: 10.1208/s12248-014-9655-y. Epub 2014 Aug 28. AAPS J. 2014. PMID: 25165039 Free PMC article.
-
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003. Clin Pharmacokinet. 2006. PMID: 16584284
-
Performance in population models for count data, part I: maximum likelihood approximations.J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):353-66. doi: 10.1007/s10928-009-9126-8. Epub 2009 Aug 4. J Pharmacokinet Pharmacodyn. 2009. PMID: 19653080
-
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.J Pharmacokinet Pharmacodyn. 2004 Aug;31(4):299-320. doi: 10.1023/b:jopa.0000042738.06821.61. J Pharmacokinet Pharmacodyn. 2004. PMID: 15563005
-
Mixed effects versus fixed effects modelling of binary data with inter-subject variability.J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):245-60. doi: 10.1007/s10928-005-0045-z. Epub 2005 Nov 7. J Pharmacokinet Pharmacodyn. 2005. PMID: 16283537 Review.
Cited by
-
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis.J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):265-277. doi: 10.1007/s10928-024-09901-2. Epub 2024 Mar 3. J Pharmacokinet Pharmacodyn. 2024. PMID: 38431923 Free PMC article. Clinical Trial.
-
An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):581-98. doi: 10.1007/s10928-014-9375-z. Epub 2014 Aug 29. J Pharmacokinet Pharmacodyn. 2014. PMID: 25168488
-
Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.Neuropsychiatr Dis Treat. 2014 May 24;10:929-52. doi: 10.2147/NDT.S62323. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 24926196 Free PMC article.
-
Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.AAPS J. 2014 Nov;16(6):1271-81. doi: 10.1208/s12248-014-9655-y. Epub 2014 Aug 28. AAPS J. 2014. PMID: 25165039 Free PMC article.
-
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.Alzheimers Dement (N Y). 2023 Jun 28;9(2):e12404. doi: 10.1002/trc2.12404. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37388759 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources